Search papers, labs, and topics across Lattice.
The CFB-GBM v2.0 dataset enhances the study of glioblastoma by providing a comprehensive longitudinal collection of imaging and clinical data from 264 patients, significantly improving Gross Tumour Volume (GTV) delineation completion from 35% to 97%. This was accomplished using a nnU-Net model pre-trained on BraTS 2021 and fine-tuned on ground-truth contours, with validation from five radiation oncologists ensuring high-quality segmentations. The dataset also includes volumetric RANO 2.0 response labels and detailed patient classification documentation, facilitating advanced research in treatment response prediction and personalized medicine.
GTV delineation accuracy skyrockets from 35% to 97%, unlocking new avenues for glioblastoma research and treatment evaluation.
Glioblastoma (GBM) is the most aggressive primary brain tumor in adults, with a median overall survival of 15 months. Longitudinal, multi-modal imaging datasets with comprehensive clinical and treatment data are essential to support the development of reproducible computational methods for treatment response prediction, disease progression modelling, and personalized medicine. We present CFB-GBM v2.0, an extension of our previously released CFB-GBM dataset comprising 264 GBM patients treated according to the standard Stupp protocol. The primary contribution of this release is the completion of Gross Tumour Volume (GTV) delineations across all available timepoints ($t_0$, $t_1$ and $t_2$), increasing the overall GTV completion rate from 35% to 97%. This was achieved using a nnU-Net model pre-trained on BraTS 2021 and fine-tuned on CFB-GBM ground-truth contours, with the generated segmentations validated by five radiation oncologists. From these longitudinal GTV annotations, volumetric RANO 2.0 response category labels were derived for all available temporality pairs ($t_0 \rightarrow t_1$, $t_0 \rightarrow t_2$ and $t_1 \rightarrow t_2$). To further ease dataset usability and reproducibility, brain masks computed with HD-BET and pre-computed radiomic features extracted with PyRadiomics are provided for each patient timepoint and MRI modality. Additionally, the WHO classification guideline (2016 vs. 2021) applicable to each patient's diagnosis is now explicitly documented. CFB-GBM v2.0 is publicly available on The Cancer Imaging Archive (TCIA) at https://www.cancerimagingarchive.net/collection/cfb-gbm .
